Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

In the third quarter of fiscal 2025, Dr. Reddy’s partner, Alvotech, completed regulatory filing seeking approval for a generic version of Amgen’s Prolia ... a rare form of head and neck ...

paving way for osteoporosis biosimilars Amgen, a U.S. pharmaceutical company with an original drug, is filing a patent lawsuit that has blocked the osteoporosis treatment drugs Prolia and Xg ...

Dr. Reddy's Laboratories Limited RDY reported third-quarter fiscal 2025 earnings of 20 cents per American Depositary Share ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...